| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 13 | 2025 | 104 | 4.860 |
Why?
|
| Immunotherapy | 14 | 2021 | 144 | 4.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2025 | 184 | 3.460 |
Why?
|
| Cell Communication | 10 | 2025 | 114 | 2.810 |
Why?
|
| Lung Neoplasms | 11 | 2024 | 495 | 2.720 |
Why?
|
| Neoplasms | 17 | 2025 | 1377 | 2.640 |
Why?
|
| Lymphocytes | 4 | 2023 | 124 | 2.240 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 1019 | 2.210 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 2024 | 34 | 2.210 |
Why?
|
| T-Lymphocytes | 12 | 2019 | 386 | 1.940 |
Why?
|
| Immunity, Innate | 8 | 2024 | 171 | 1.620 |
Why?
|
| Tumor Escape | 8 | 2025 | 17 | 1.590 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2020 | 18 | 1.580 |
Why?
|
| Antibodies, Monoclonal | 5 | 2025 | 306 | 1.560 |
Why?
|
| Kidney Neoplasms | 8 | 2021 | 80 | 1.540 |
Why?
|
| Antigens, Neoplasm | 6 | 2025 | 90 | 1.300 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2020 | 27 | 1.290 |
Why?
|
| Animals | 49 | 2025 | 16992 | 1.180 |
Why?
|
| Immunologic Surveillance | 3 | 2025 | 10 | 1.170 |
Why?
|
| Immunomodulation | 4 | 2019 | 17 | 1.140 |
Why?
|
| Adaptive Immunity | 5 | 2019 | 34 | 1.140 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2024 | 223 | 1.120 |
Why?
|
| Cytokines | 6 | 2021 | 678 | 1.080 |
Why?
|
| Mice | 31 | 2025 | 6644 | 1.050 |
Why?
|
| Thymus Gland | 7 | 2004 | 76 | 0.960 |
Why?
|
| Mitochondria | 4 | 2024 | 523 | 0.910 |
Why?
|
| Lymphoma, T-Cell | 6 | 2003 | 29 | 0.880 |
Why?
|
| Research Support as Topic | 1 | 2025 | 89 | 0.880 |
Why?
|
| Biomedical Technology | 1 | 2024 | 12 | 0.830 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 32 | 0.800 |
Why?
|
| Humans | 47 | 2026 | 43102 | 0.790 |
Why?
|
| Schools, Medical | 1 | 2025 | 208 | 0.780 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 694 | 0.740 |
Why?
|
| Cultural Diversity | 1 | 2024 | 193 | 0.730 |
Why?
|
| Cell Line, Tumor | 14 | 2025 | 2676 | 0.720 |
Why?
|
| Receptors, Notch | 4 | 2020 | 38 | 0.680 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2017 | 116 | 0.680 |
Why?
|
| Signal Transduction | 16 | 2021 | 2157 | 0.670 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 12 | 0.660 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 291 | 0.650 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 69 | 0.640 |
Why?
|
| Dendritic Cells | 2 | 2019 | 132 | 0.620 |
Why?
|
| Biomedical Research | 1 | 2025 | 502 | 0.620 |
Why?
|
| Fas Ligand Protein | 4 | 2015 | 17 | 0.610 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 512 | 0.610 |
Why?
|
| NF-kappa B | 3 | 2017 | 358 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 220 | 0.540 |
Why?
|
| Lymphocyte Activation | 9 | 2025 | 249 | 0.540 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 11 | 0.530 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 5 | 0.520 |
Why?
|
| Fibrosarcoma | 1 | 2017 | 8 | 0.520 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 173 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 5 | 2025 | 1869 | 0.510 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 968 | 0.500 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 48 | 0.500 |
Why?
|
| Mice, Knockout | 5 | 2025 | 1035 | 0.500 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 30 | 0.500 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 91 | 0.500 |
Why?
|
| Boronic Acids | 4 | 2010 | 21 | 0.490 |
Why?
|
| Pyrazines | 4 | 2010 | 32 | 0.490 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 1723 | 0.480 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 8 | 0.480 |
Why?
|
| Immune System Diseases | 1 | 2015 | 21 | 0.470 |
Why?
|
| MicroRNAs | 1 | 2021 | 518 | 0.440 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2025 | 104 | 0.410 |
Why?
|
| Membrane Proteins | 6 | 2024 | 561 | 0.410 |
Why?
|
| alpha-Defensins | 2 | 2025 | 22 | 0.390 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 665 | 0.380 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2010 | 12 | 0.380 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 18 | 0.360 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 150 | 0.360 |
Why?
|
| Neoplasm Transplantation | 7 | 2010 | 129 | 0.350 |
Why?
|
| Virus Diseases | 1 | 2011 | 27 | 0.350 |
Why?
|
| Aging | 3 | 2022 | 783 | 0.350 |
Why?
|
| Apoptosis | 8 | 2021 | 1568 | 0.350 |
Why?
|
| Organ Specificity | 3 | 2024 | 141 | 0.350 |
Why?
|
| Adoptive Transfer | 3 | 2025 | 53 | 0.340 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2010 | 4 | 0.330 |
Why?
|
| Calcium | 5 | 2017 | 491 | 0.330 |
Why?
|
| Cell Count | 2 | 2013 | 145 | 0.330 |
Why?
|
| Inflammation | 4 | 2024 | 758 | 0.330 |
Why?
|
| Female | 19 | 2026 | 24698 | 0.320 |
Why?
|
| Mastocytoma | 1 | 2010 | 4 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 133 | 0.320 |
Why?
|
| Antigen Presentation | 1 | 2009 | 58 | 0.300 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2008 | 10 | 0.300 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2010 | 69 | 0.280 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 29 | 0.280 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2007 | 1 | 0.280 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1070 | 0.270 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 49 | 0.250 |
Why?
|
| Male | 14 | 2026 | 23409 | 0.250 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 241 | 0.250 |
Why?
|
| Ascites | 3 | 2000 | 6 | 0.250 |
Why?
|
| Homeostasis | 4 | 2022 | 192 | 0.240 |
Why?
|
| Receptors, Natural Killer Cell | 2 | 2024 | 4 | 0.240 |
Why?
|
| Monitoring, Immunologic | 1 | 2025 | 6 | 0.240 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1596 | 0.230 |
Why?
|
| Chemokines | 2 | 2016 | 96 | 0.230 |
Why?
|
| Appalachian Region | 1 | 2025 | 6 | 0.230 |
Why?
|
| Periodontitis | 1 | 2026 | 62 | 0.230 |
Why?
|
| ROC Curve | 1 | 2025 | 159 | 0.220 |
Why?
|
| Epitopes | 1 | 2025 | 157 | 0.220 |
Why?
|
| Colitis, Ulcerative | 2 | 2025 | 70 | 0.210 |
Why?
|
| Medically Underserved Area | 1 | 2025 | 120 | 0.210 |
Why?
|
| Colon | 2 | 2025 | 120 | 0.210 |
Why?
|
| Colitis | 1 | 2025 | 71 | 0.210 |
Why?
|
| Ethicists | 1 | 2024 | 5 | 0.210 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2024 | 17 | 0.210 |
Why?
|
| Nervous System Diseases | 1 | 2024 | 77 | 0.210 |
Why?
|
| Memory Disorders | 1 | 2024 | 77 | 0.210 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 118 | 0.200 |
Why?
|
| Flavoproteins | 2 | 2000 | 16 | 0.200 |
Why?
|
| Flow Cytometry | 3 | 2015 | 411 | 0.200 |
Why?
|
| Thymus Extracts | 1 | 2003 | 5 | 0.200 |
Why?
|
| Calcium-Binding Proteins | 3 | 2019 | 81 | 0.190 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 38 | 0.190 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 100 | 0.190 |
Why?
|
| Astrocytes | 1 | 2024 | 244 | 0.180 |
Why?
|
| Aged | 3 | 2025 | 8214 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 166 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 117 | 0.180 |
Why?
|
| Immunoblotting | 2 | 2015 | 181 | 0.180 |
Why?
|
| Rural Population | 1 | 2025 | 373 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 61 | 0.180 |
Why?
|
| Research Design | 1 | 2024 | 385 | 0.180 |
Why?
|
| Genomics | 1 | 2024 | 293 | 0.180 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 13 | 0.170 |
Why?
|
| Poly I-C | 1 | 2021 | 7 | 0.170 |
Why?
|
| Withanolides | 1 | 2021 | 10 | 0.170 |
Why?
|
| Universities | 1 | 2025 | 559 | 0.170 |
Why?
|
| Cell Survival | 3 | 2016 | 945 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 46 | 0.170 |
Why?
|
| Enterotoxins | 1 | 2021 | 33 | 0.170 |
Why?
|
| Hippocampus | 1 | 2024 | 594 | 0.170 |
Why?
|
| Organoids | 1 | 2021 | 37 | 0.170 |
Why?
|
| Carcinoma, Large Cell | 1 | 2020 | 3 | 0.160 |
Why?
|
| Cell Differentiation | 3 | 2019 | 638 | 0.160 |
Why?
|
| Crohn Disease | 1 | 2021 | 71 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 65 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 187 | 0.160 |
Why?
|
| RNA Interference | 1 | 2021 | 247 | 0.160 |
Why?
|
| Calcium Signaling | 3 | 2017 | 107 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 91 | 0.150 |
Why?
|
| Brain | 2 | 2024 | 1472 | 0.150 |
Why?
|
| Caspase 8 | 2 | 2010 | 32 | 0.150 |
Why?
|
| Models, Immunological | 1 | 2019 | 21 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 299 | 0.140 |
Why?
|
| Leukemia | 2 | 2016 | 54 | 0.140 |
Why?
|
| Protease Inhibitors | 2 | 2008 | 54 | 0.140 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2015 | 6 | 0.130 |
Why?
|
| Antigens, CD1 | 1 | 2017 | 5 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1124 | 0.130 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 73 | 0.130 |
Why?
|
| Aging, Premature | 1 | 2017 | 6 | 0.130 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 11 | 0.130 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 224 | 0.130 |
Why?
|
| Osteopontin | 1 | 2017 | 46 | 0.130 |
Why?
|
| Trialkyltin Compounds | 1 | 2016 | 2 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 49 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 704 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 934 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1455 | 0.120 |
Why?
|
| Butyrates | 1 | 2016 | 34 | 0.120 |
Why?
|
| Nystatin | 1 | 2016 | 6 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2021 | 735 | 0.120 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2015 | 3 | 0.120 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 35 | 0.120 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2017 | 187 | 0.120 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.120 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 53 | 0.120 |
Why?
|
| Genes, ras | 1 | 2015 | 24 | 0.120 |
Why?
|
| Bystander Effect | 1 | 2015 | 15 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 259 | 0.110 |
Why?
|
| Genetic Engineering | 1 | 2015 | 37 | 0.110 |
Why?
|
| Autoimmunity | 1 | 2015 | 58 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 140 | 0.110 |
Why?
|
| Middle Aged | 3 | 2026 | 12222 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2015 | 51 | 0.110 |
Why?
|
| Ubiquitin | 1 | 2015 | 81 | 0.110 |
Why?
|
| Benzo(a)pyrene | 1 | 2016 | 128 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 74 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 220 | 0.110 |
Why?
|
| Melanoma | 1 | 2015 | 110 | 0.110 |
Why?
|
| Air Pollutants | 1 | 2016 | 130 | 0.110 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 165 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 384 | 0.100 |
Why?
|
| United States | 1 | 2025 | 5205 | 0.100 |
Why?
|
| Graft Rejection | 2 | 2019 | 43 | 0.100 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 201 | 0.100 |
Why?
|
| Mice, SCID | 2 | 2015 | 158 | 0.100 |
Why?
|
| Mutation | 2 | 2015 | 1177 | 0.100 |
Why?
|
| Gene Expression | 1 | 2016 | 701 | 0.100 |
Why?
|
| Caspase 3 | 2 | 2016 | 227 | 0.090 |
Why?
|
| Ligands | 2 | 2020 | 388 | 0.090 |
Why?
|
| Cell Lineage | 2 | 2021 | 104 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 279 | 0.090 |
Why?
|
| DNA Fragmentation | 2 | 2003 | 98 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 16 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 529 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2021 | 1621 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2016 | 161 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 355 | 0.080 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2000 | 7 | 0.080 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2010 | 3 | 0.080 |
Why?
|
| Interferon-gamma | 2 | 2003 | 269 | 0.080 |
Why?
|
| Lymphocyte Cooperation | 1 | 2010 | 5 | 0.080 |
Why?
|
| Clonal Deletion | 1 | 2010 | 3 | 0.080 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 4 | 0.080 |
Why?
|
| Immunologic Memory | 1 | 2010 | 42 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 43 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 74 | 0.080 |
Why?
|
| Autoantigens | 1 | 2010 | 87 | 0.080 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2010 | 65 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 152 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 41 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 83 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2026 | 2544 | 0.060 |
Why?
|
| Immune System | 1 | 2007 | 41 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 310 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 59 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 73 | 0.060 |
Why?
|
| Epitope Mapping | 1 | 2025 | 32 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 65 | 0.060 |
Why?
|
| Surface Plasmon Resonance | 1 | 2025 | 42 | 0.060 |
Why?
|
| Radiation Chimera | 1 | 2004 | 8 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 19 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2004 | 55 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 47 | 0.050 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 5 | 0.050 |
Why?
|
| Atrophy | 1 | 2004 | 51 | 0.050 |
Why?
|
| Phosphates | 1 | 2023 | 54 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2026 | 719 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 532 | 0.050 |
Why?
|
| Organ Size | 1 | 2003 | 170 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2004 | 172 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2026 | 1081 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2021 | 2 | 0.040 |
Why?
|
| Mucin-6 | 1 | 2021 | 7 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 2000 | 7 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2021 | 101 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 22 | 0.040 |
Why?
|
| Nucleosomes | 1 | 2000 | 30 | 0.040 |
Why?
|
| Culture Media | 1 | 2000 | 96 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 234 | 0.040 |
Why?
|
| Thymosin | 1 | 2000 | 3 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 20 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 144 | 0.040 |
Why?
|
| Biological Factors | 1 | 2000 | 6 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2000 | 109 | 0.040 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 22 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2000 | 62 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 508 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 118 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 311 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2000 | 97 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 408 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 64 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 347 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 238 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 197 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 134 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2019 | 64 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2019 | 47 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2000 | 182 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 378 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1009 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2021 | 434 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 861 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1067 | 0.030 |
Why?
|
| Sperm Count | 1 | 2017 | 28 | 0.030 |
Why?
|
| Sperm Motility | 1 | 2017 | 47 | 0.030 |
Why?
|
| U937 Cells | 1 | 2016 | 31 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2016 | 33 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 102 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 154 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 21 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2016 | 41 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 108 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2016 | 53 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 105 | 0.030 |
Why?
|
| Lung | 1 | 2019 | 492 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 51 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 137 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 157 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 71 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 247 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 206 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 296 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 259 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 6 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 883 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 116 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 83 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 152 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Cell Movement | 1 | 2016 | 655 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 154 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1180 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1542 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 183 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 139 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 200 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 213 | 0.020 |
Why?
|
| Adult | 1 | 2026 | 13872 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 462 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1604 | 0.020 |
Why?
|
| Perforin | 1 | 2008 | 11 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 114 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 536 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 307 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2006 | 22 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 518 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 712 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 49 | 0.010 |
Why?
|
| Gallic Acid | 1 | 2000 | 11 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 139 | 0.010 |
Why?
|